(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases...
Stats | |
---|---|
本日の出来高 | 6 585.00 |
平均出来高 | 2 534.00 |
時価総額 | 88.44B |
EPS | €0 ( 2024-04-25 ) |
次の収益日 | ( €0 ) 2024-07-26 |
Last Dividend | €0.570 ( 2023-07-06 ) |
Next Dividend | €0 ( N/A ) |
P/E | 12.10 |
ATR14 | €0.0880 (0.21%) |
ボリューム 相関
Bristol-Myers Squibb Co 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Bristol-Myers Squibb Co 相関 - 通貨/商品
Bristol-Myers Squibb Co 財務諸表
Annual | 2023 |
収益: | €45.01B |
総利益: | €34.31B (76.24 %) |
EPS: | €3.88 |
FY | 2023 |
収益: | €45.01B |
総利益: | €34.31B (76.24 %) |
EPS: | €3.88 |
FY | 2022 |
収益: | €46.16B |
総利益: | €36.02B (78.04 %) |
EPS: | €2.97 |
FY | 2021 |
収益: | €46.39B |
総利益: | €36.45B (78.57 %) |
EPS: | €3.15 |
Financial Reports:
No articles found.
Bristol-Myers Squibb Co Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€0.540 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0.570 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.215 | 1999-06-30 |
Last Dividend | €0.570 | 2023-07-06 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 97 | -- |
Total Paid Out | €33.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.93 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.68 | |
Div. Directional Score | 8.19 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VH2.F | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
EOAN.DE | Ex Dividend Junior | 2023-05-18 | Annually | 0 | 0.00% | |
NWT.DE | Ex Dividend Knight | 2023-08-03 | Quarterly | 0 | 0.00% | |
AISF.F | Ex Dividend Knight | 2023-08-18 | Semi-Annually | 0 | 0.00% | |
GUI.DE | Ex Dividend Knight | 2023-08-24 | Semi-Annually | 0 | 0.00% | |
QCI.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
BNR.DE | Ex Dividend Knight | 2023-06-16 | Annually | 0 | 0.00% | |
INS.DE | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
SY1.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
DAM.DE | Ex Dividend Junior | 2023-05-10 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.178 | 1.500 | 6.43 | 9.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0843 | 1.200 | 7.19 | 8.63 | [0 - 0.3] |
returnOnEquityTTM | 0.263 | 1.500 | 8.19 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.591 | -1.000 | 4.09 | -4.09 | [0 - 1] |
currentRatioTTM | 1.427 | 0.800 | 7.86 | 6.29 | [1 - 3] |
quickRatioTTM | 1.237 | 0.800 | 7.43 | 5.94 | [0.8 - 2.5] |
cashRatioTTM | 0.515 | 1.500 | 8.25 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.436 | -1.500 | 2.74 | -4.11 | [0 - 0.6] |
interestCoverageTTM | 8.08 | 1.000 | 8.12 | 8.12 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.82 | 2.00 | 7.73 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.23 | 2.00 | 6.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.409 | -1.500 | 4.36 | -6.55 | [0 - 2.5] |
grossProfitMarginTTM | 0.762 | 1.000 | 0.627 | 0.627 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.209 | 1.000 | 7.82 | 7.82 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.334 | 1.000 | 9.25 | 9.25 | [0.2 - 2] |
assetTurnoverTTM | 0.473 | 0.800 | -0.180 | -0.144 | [0.5 - 2] |
Total Score | 10.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.47 | 1.000 | 8.94 | 0 | [1 - 100] |
returnOnEquityTTM | 0.263 | 2.50 | 8.84 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.23 | 2.00 | 7.92 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.258 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.82 | 2.00 | 7.73 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.591 | 1.500 | 4.09 | -4.09 | [0 - 1] |
pegRatioTTM | 0.194 | 1.500 | -2.04 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.308 | 1.000 | 4.80 | 0 | [0.1 - 0.5] |
Total Score | 5.68 |
Bristol-Myers Squibb Co
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。